A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...

I found that so many people were making their own GLP-1s and taking smaller amounts than normally prescribed,” she said. “I ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

Eli Lilly (LLY) is reportedly seeking to oppose a lawsuit filed by compounding pharmacies over the FDA's determination that ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

StudyFinds' Dr. Faith Colemans explains why shopping for weight loss drugs online may save you money but endanger your health ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand version in early 2025 ...

"FDA continues to monitor supply and demand for these products." Since the shortage began, specialty and compounding pharmacies have been allowed to sell off-brand versions of the weight loss drug.

Related: 1 in 8 U.S. Adults Have Taken Ozempic or Similar Drugs, According to a New Survey Since the shortage began, specialty and compounding ... stated that semaglutide, the active ingredient ...